Risk factors

The risk profile shifted away from the terminated Roosevelt transaction toward internal controls, Nasdaq listing, and ongoing operating losses.

Loss of our largest customer who represented nearly half of our sales volume forced major operational restructuring and plant closure.

Rein Therapeutics faces going concern doubts after reporting a $50.6 million operating loss in 2025 and an accumulated deficit of $401.3 million. The company indefinite paused development of product candidate LTI-01 due to capital limitations, increasing reliance on lead candidate LTI-03. Macroeconomic pressures include a 10% tariff on imports from China announced in February 2025.

Foreign net operating loss carryforwards of $5.6 million face expiration risks starting in 2028. Dilution risks increased significantly from preferred stock convertibility and equity awards. Data privacy, security, and potential litigation risks threaten brand reputation and operational costs.

Shoe Station Group added execution risks around its legacy Shoe Carnival stores and e-commerce channel.

Company dropped its going concern warning but added trade and tariff risks for manufacturing.

Added disclosure of legal proceedings risk citing the WSCC Project adverse ruling. Updated commodity price risk to explicitly mention inflation and tariffs. Revised customer risk to specify the NYSE American listing standards for controlled company status.

SANUWAVE added internal control material weakness risks and disclosed a $44.2 million NOL expiration from ownership changes. The company highlighted debt refinancing, net income of $11.8 million, and positive operating income for 2025. Reimbursement changes for wound care products like skin substitutes could indirectly reduce demand for the UltraMIST system.

Spero Therapeutics faces heightened operational risks regarding clinical trial uncertainties, debt financing needs, and external macroeconomic pressures like new tariffs and tax laws.

Labor union coverage and employee headcount in Mexico decreased significantly year-over-year. Net losses and cash used in operations widened considerably. Foreign currency risk disclosures added unexpected losses from a stronger Mexican Peso.

AI adoption, misuse, and competitive technology gaps are now explicit risks for Ulta Beauty.

Upstream Bio added several new risk factors relating to its sole product candidate verekitug, clinical development funding, intellectual property, and tax law changes.